Women's Headache Center, Department of Gynecology and Obstetrics, University of Torino, Via Ventimiglia 3, 10126 Turin, Italy.
Neurol Sci. 2011 May;32 Suppl 1(Suppl 1):S99-104. doi: 10.1007/s10072-011-0547-y.
Menstrually related migraine (MRM) is a particularly difficult-to-treat pain condition, associated with substantial disability. Aim of this study was to compare the efficacy and safety of frovatriptan and zolmitriptan in the treatment of MRM attacks, analyzing data from a multicenter, randomized, double blind, cross-over study. We analyzed the subset of 76 regularly menstruating women who participated in one head-to-head multicenter, randomized, double blind, cross-over clinical trial and who took the study drugs to treat MRM attacks. In a randomized sequence, each patient received frovatriptan 2.5 mg or zolmitriptan 2.5 mg: after treating three episodes of migraine in no more than 3 months with the first treatment, the patient had to switch to the other treatment. MRM was defined according to the criteria listed in the Appendix of the last Classification of Headache disorders of the International Headache Society. A total of 73 attacks, classified as MRM, were treated with frovatriptan and 65 with zolmitriptan. Rate of pain relief at 2 h was 52% for frovatriptan and 53% for zolmitriptan (p = NS), while rate of pain free at 2 h was 22 and 26% (p = NS), respectively. At 24 h, 74 and 83% of frovatriptan-treated and 69 and 82% of zolmitriptan-treated patients were pain free and had pain relief, respectively (p = NS). Recurrence at 24 h was significantly (p < 0.05) lower with frovatriptan (15 vs. 22% zolmitriptan). Frovatriptan proved to be effective in the immediate treatment of MRM attacks, similarly to zolmitriptan, but showed lower recurrence rates, and thus a better sustained relief.
与大量残疾相关的经期相关偏头痛（MRM）是一种特别难以治疗的疼痛病症。本研究旨在比较曲普坦和佐米曲普坦治疗 MRM 发作的疗效和安全性，分析一项多中心、随机、双盲、交叉研究的数据。我们分析了参加一项头对头多中心、随机、双盲、交叉临床试验的 76 名经常月经的女性亚组，她们服用研究药物治疗 MRM 发作。按照随机顺序，每位患者接受曲普坦 2.5mg 或佐米曲普坦 2.5mg：用第一种治疗方法在 3 个月内最多治疗三次偏头痛发作后，患者必须改用另一种治疗方法。MRM 根据国际头痛协会最后头痛障碍分类附录中列出的标准定义。共治疗了 73 次被归类为 MRM 的发作，用曲普坦治疗了 73 次，用佐米曲普坦治疗了 65 次。曲普坦在 2 小时时缓解疼痛的比例为 52%，佐米曲普坦为 53%（p=NS），而在 2 小时时无疼痛的比例分别为 22%和 26%（p=NS）。在 24 小时时，74%和 83%的曲普坦治疗患者和 69%和 82%的佐米曲普坦治疗患者无疼痛且疼痛缓解（p=NS）。24 小时时的复发率显著（p<0.05）较低，曲普坦为 15%，佐米曲普坦为 22%。曲普坦在 MRM 发作的即时治疗中证明是有效的，与佐米曲普坦相似，但显示出较低的复发率，从而提供更好的持续缓解。
